Allogeneic cellular immunotherapies hold a great promise for cancer treatment owing to
their potential cost-effectiveness, scalability and on-demand availability. However, immune …

Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies
has improved the treatment and prognosis of many patients. Nevertheless, most cancers are …

Siglecs are a family of sialic acid–binding receptors expressed by cells of the immune
system and a few other cell types capable of modulating immune cell functions upon …

Cancer cells can evade natural killer (NK) cell activity, thereby limiting anti-tumor immunity.
To reveal genetic determinants of susceptibility to NK cell activity, we examined interacting …

The Siglecs (sialic acid-binding immunoglobulin-like lectins) are glycoimmune checkpoint
receptors that suppress immune cell activation upon engagement of cognate sialoglycan …

CRISPR-based technologies represent a major breakthrough in biomedical science as they
offer a powerful platform for unbiased screening and functional genomics in various fields …

Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune
responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated …

Glycosylation of proteins and lipids in mammals is essential for embryogenesis and the
development of all tissues. Analyses of glycosylation mutants in cultured mammalian cells …

Cell surface glycosylation has a variety of functions, and its dysregulation in cancer
contributes to impaired signaling, metastasis and the evasion of the immune responses …

Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …